Mirum Pharmaceuticals, Inc. (MIRM) Tops Q1 EPS by 17c

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q1 EPS of ($1.17), $0.17 better than the analyst estimate of ($1.34). Revenue for the quarter came in at $12.9 million versus the consensus estimate of $8.46 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins